SCHEMBL13989142

SCHEMBL13989142

CC(=O)Cc1ccc2ccccn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37
CDK7 P50613 1/20 0.37
TYRO3 Q06418 1/20 0.37
LRRK2 Q5S007 1/20 0.37
AURKB Q96GD4 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 7/20 0.35
RAB9A P51151 4/20 0.35
BAZ2B Q9UIF8 3/20 0.35
BAZ2A Q9UIF9 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229293 0.84 AKR1B1 (0.42) L3MBTL1HTTATMKMT2AKDM4E
SCHEMBL15491630 0.75 ALDH1A1 (0.44) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL17519485 0.71 GGPS1 (0.54) KMT2AKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL6949233 0.71 KDM4E (0.37) L3MBTL1KMT2AKDM4ERAB9ASMN1; SMN2
SCHEMBL6222799 0.70 ALDH1A1 (0.34) L3MBTL1KMT2AKDM4ERAB9AALDH1A1
SCHEMBL1722529 0.70 PTGS2 (0.46) HTTKMT2AKDM4EALDH1A1MEN1
SCHEMBL7073068 0.69 TBXAS1 (0.44) L3MBTL1HTTATMKMT2AKDM4E
SCHEMBL8127371 0.68 TBXAS1 (0.55) L3MBTL1HTTATMKDM4ESMN1; SMN2
SCHEMBL6244092 0.68 TBXAS1 (0.50) MAPTCYP2D6
SCHEMBL5425400 0.68 L3MBTL1 (0.37) L3MBTL1HTTATMKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023081306-A1 INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-05-11 WO disclosed
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 MAP4K4 4082/4885ABL1 3045/4885MAPK8 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.